Ranibizumab Treatment for Retinal Vein Occlusion

• Status: Unknown status
• Trial end date: 2019-09-01
• Target enrollment: 0
• Participant gender: All

Summary

In retinal vein occlusion, predictive factors for visual outcome after ranibizumab treatment have not been evaluated comprehensively. Therefore, we have planned to analyze predictors for visual outcome from a viewpoint of electrophysiology and biomarkers besides morphological features by SD-OCT.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Kyoto University, Graduate School of Medicine
• Collaborator: Novartis
• Treatments: Ranibizumab

Criteria

Inclusion Criteria:

• Signed informed consent form

• Male or female of aged 18 years or older

• Macula edema secondary to BRVO/CRVO

• Decrease of VA due to macular edema

Exclusion Criteria:

• Prior episode of RVO

• Previous treatment with anti-VEGF drugs or corticosteroid or grid laser photocoagulation (study eye)

• Ocular disorders in the study eye that may confound interpretation of study results

• History of vitrectomy surgery, submacular surgery, or other surgical intervention for RVO

• The pregnant or lactating woman